Abstract
The HeartMate 3 risk score (HM3RS) was developed from the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) clinical trial to predict 1 and 2 year mortality after left ventricular assist device implantation. However, it has not been validated in a real-world population, especially after the heart transplant allocation system change on October 18, 2018. In this multicenter retrospective analysis, we found that HM3RS did not predict 1 and 2 year outcomes in the contemporary era, highlighting the need to revise this risk prediction tool in the real-world setting.
Original language | English |
---|---|
Article number | 10.1097/MAT.0000000000002343 |
Journal | ASAIO Journal |
DOIs | |
State | Accepted/In press - 2024 |
Keywords
- Heartmate 3 risk score
- left ventricular assist device
- MOMENTUM 3
- UNOS heart transplant allocation system